April 22, 2024

Scopolamine Market Poised for Rapid Growth Due to Rising Prevalence of Motion Sickness

It works by blocking muscarinic acetylcholine receptors in the brain to reduce vomiting and nausea caused due to motion or due to anesthesia and surgery. The increasing prevalence of motion sickness among all age groups during means of transportation like air travel, sea travel and road travel is driving the demand for effective anti-emetic drugs like scopolamine.

The global scopolamine market size is estimated to be valued at US$ 4235.74 Mn in 2024 and is expected to exhibit a CAGR of 3.8% over the forecast period from 2024 to 2030.

Key players operating in the scopolamine market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc.

Key Takeaways

Key players: The major players operating in the Scopolamine Market Size are focusing on geographic expansion and new product launches. For instance, in 2021, Bausch Health Companies acquired Synergy Pharmaceuticals to enhance its gastroenterology portfolio.

Key opportunities: Growing geriatric population suffering from nausea, vomiting and motion sickness during transportation is expected to offer significant growth opportunities. Increasing preference for minimally invasive procedures is also supporting the demand.

Global expansion: The Asia Pacific region offers lucrative opportunities for expansion owing to rising healthcare investments, growing medical tourism industry and increasing awareness about motion sickness. Emerging markets like China and India are expected to witness high demand.

Market Drivers

Rising prevalence of motion sickness: Motion sickness is a very common problem affecting around 50% of the general population. Advancing means of transportation and growing tourism industry has increased the prevalence of motion sickness worldwide.

Increasing preference for non-invasive treatment options: Non-invasive drugs like scopolamine patches and scopolamine pills are preferred over other invasive options for treatment of nausea and vomiting due to their convenience and ease of use. This is a major driver boosting the scopolamine market growth.

PEST Analysis
Political: Healthcare policies of governments play a major role in regulating the Scopolamine market. Governments undertake initiatives to improve access to healthcare.
Economic: The Scopolamine market is dependent on healthcare spending by governments and individuals. Cost containment policies can impact the industry.
Social: Rising incidences of motion sickness and other medical conditions drive the demand for Scopolamine drugs. Increasing health awareness increases the scope of treatment using Scopolamine.
Technological: Advancements in drug delivery methods enhance the efficacy of Scopolamine drugs. Research focuses on developing new formulations and applications.

Geographical regions with high market concentration in terms of value include North America and Europe owing to sophisticated healthcare infrastructure and high spending capabilities. Asia Pacific is the fastest growing region due to improving access to healthcare, rising living standards and a large patient pool. China and India present lucrative opportunities.

The United States accounts for the major share in North America due to a well-established healthcare system and favorable reimbursement policies. Presence of key industry players also supports market growth. Germany, France and the United Kingdom dominate the European market. Rapid economic development and growing medical tourism strengthen the Asia Pacific markets.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it